Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • +USFDA Observation

    Tag: +usfda observation

    You Searched For "+USFDA Observation"
    Shilpa Medicare Telangana facility gets EIR from USFDA

    Shilpa Medicare Telangana facility gets EIR from USFDA

    Medical Dialogues Bureau26 Oct 2019 11:46 AM IST
    "The USFDA has concluded that the inspection classification of Jadcherla facility was "voluntary action indicated". This facility is in an acceptable...
    Cipla gets 12 USFDA observations for Goa facility

    Cipla gets 12 USFDA observations for Goa facility

    Medical Dialogues Bureau30 Sept 2019 3:15 PM IST
    "The United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Goa manufacturing facility from September 16-27, 2019,"...
    Shilpa Medicare gets 2 USFDA observations for Telangana facility

    Shilpa Medicare gets 2 USFDA observations for Telangana facility

    Medical Dialogues Bureau9 Sept 2019 11:50 AM IST
    The US Food and Drug Administration (USFDA) inspected the company's finished dosage formulation facility located at Pharmaceutical Formulations SEZ,...
    Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

    Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

    Medical Dialogues Bureau8 Aug 2019 10:00 AM IST
    The company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila...
    Sun Pharma and SPARC

    Sun Pharma and SPARC's XELPROS gets USFDA approval

    Medical Dialogues Bureau15 Sept 2018 4:32 PM IST
    US Food and Drug Administration (USFDA) has approved the SPARC new drug application of XELPROS, used to reduce glaucoma open-angle glaucoma or ocular...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok